The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS)


Citar

Texto integral

Resumo

In this genomic era of addiction medicine, ideal treatment planning begins with genetic screening to determine neurogenetic antecedents of the Reward Deficiency Syndrome (RDS) phenotype. Patients suffering from endotype addictions, both substance and behavioral, and other mental health/comorbid disorders that share the neurobiological commonality of dopamine dysfunction, are ideal candidates for RDS solutions that facilitate dopamine homeostasis, addressing the cause, rather than symptoms. Our goal is to promote the interplay of molecular biology and recovery as well as provide evidence linked to RDS and its scientific basis to primary care physicians and others. This was an observational case study with a retrospective chart review in which an RDS treatment plan that utilized Genetic Addiction Risk Severity (GARS) analysis to evaluate neurogenetic challenges was used in order to develop appropriate short- and long-term pharmaceutical and nutraceutical interventions. A Substance Use Disorder (SUD) treatment-resistant patient was successfully treated utilizing the GARS test and RDS science. The RDS Solution Focused Brief Therapy (RDS-SFBT) and the RDS Severity of Symptoms Scale (SOS) may provide clinicians with a useful tool for establishing neurological balance and helping patients to achieve selfefficacy, self-actualization, and prosperity.

Sobre autores

Elizabeth Gilley

, The Elle Foundation

Autor responsável pela correspondência
Email: info@benthamscience.net

Abdalla Bowirrat

Department of Molecular Biology and Adelson School of Medicine, Ariel University

Email: info@benthamscience.net

Ashim Gupta

, Future Biologics

Email: info@benthamscience.net

John Giordano

, The National Institute of Holistic & Addiction Studies

Email: info@benthamscience.net

Catherine Dennen

Department of Family Medicine, Jefferson Health Northeast

Email: info@benthamscience.net

Eric Braverman

, The Kenneth Blum Institute of Behavior & Neurogenetics

Email: info@benthamscience.net

Rajendra Badgaiyan

Department of Psychiatry, Long School of Medicine, University of Texas Medical Center,

Email: info@benthamscience.net

Thomas McLaughlin

, The Kenneth Blum Institute of Behavior & Neurogenetics

Email: info@benthamscience.net

David Baron

Division of Addiction Research & Education, Center for Psychiatry, Medicine, Primary Care (Office of Provost), Western University Health Sciences

Email: info@benthamscience.net

Kenneth Blum

, The Kenneth Blum Institute of Behavior & Neurogenetics

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Lozano, Ó.M.; Rojas, A.J.; Fernández Calderón, F. Psychiatric comorbidity and severity of dependence on substance users: How it impacts on their health-related quality of life? J. Ment. Health, 2017, 26(2), 119-126. doi: 10.1080/09638237.2016.1177771 PMID: 27128492
  2. el-Guebaly, N. Concurrent substance-related disorders and mental illness: the North American experience. World Psychiatry, 2004, 3(3), 182-187. PMID: 16633492
  3. Blum, K.; Badgaiyan, R.D.; Agan, G.; Fratantonio, J.; Simpatico, T.; Febo, M.; Haberstick, B.C.; Smolen, A.; Gold, M.S. Molecular genetic testing in reward deficiency syndrome (RDS): Facts and fiction. J. Reward Defic. Syndr., 2015, 1(1), 65-68. doi: 10.17756/jrds.2015-009 PMID: 26052557
  4. Blum, K.; Braverman, E.R.; Holder, J.M.; Lubar, J.F.; Monastra, V.J.; Miller, D.; Lubar, J.O.; Chen, T.J.H.; Comings, D.E. Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoactive Drugs, 2000, 32(sup1 Suppl.), 1-112-1-112. doi: 10.1080/02791072.2000.10736099 PMID: 11280926
  5. Moberg, C.A.; Humphreys, K. Exclusion criteria in treatment research on alcohol, tobacco and illicit drug use disorders: A review and critical analysis. Drug Alcohol Rev., 2017, 36(3), 378-388. doi: 10.1111/dar.12438 PMID: 27324921
  6. Blum, K.; Thompson, B.; Demotrovics, Z.; Femino, J.; Giordano, J.; Oscar-Berman, M.; Teitelbaum, S.; Smith, D.E.; Roy, A.K.; Agan, G.; Fratantonio, J.; Badgaiyan, R.D.; Gold, M.S. The molecular neurobiology of twelve steps program & fellowship: Connecting the dots for recovery. J. Reward Defic. Syndr., 2015, 1(1), 46-64. doi: 10.17756/jrds.2015-008 PMID: 26306329
  7. Baron, D.; Blum, K.; Chen, A.; Gold, M.; Badgaiyan, R.D. Conceptualizing addiction from an osteopathic perspective: Dopamine homeostasis. J. Am. Osteopath. Assoc., 2018, 118(2), 115-118. PMID: 29379966
  8. Edwards, D.; Roy, A.K., III; Boyett, B.; Badgaiyan, R.D.; Thanos, P.K.; Baron, D.; Hauser, M.; Badgaiyan, S.; Brewer, R.; Siwicki, D.B.; Downs, W.; Smith, D.E.; Blum, K. Addiction by any other name is still addiction: Embracing molecular neurogenetic/epigenetic basis of reward deficiency. J. Addict., 2020, 6(1), 1-4. doi: 10.17756/jas.2020-043 PMID: 32432229
  9. Blum, K.; Sheridan, P.J.; Wood, R.C.; Braverman, E.R.; Chen, T.J.H. phd, J.G.C.; Comings, D.E. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J. R. Soc. Med., 1996, 89(7), 396-400. doi: 10.1177/014107689608900711 PMID: 8774539
  10. Diana, M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front. Psychiatry, 2011, 2. doi: 10.3389/fpsyt.2011.00064
  11. Dackis, C.A.; Gold, M.S. New concepts in cocaine addiction: The dopamine depletion hypothesis. Neurosci. Biobehav. Rev., 1985, 9(3), 469-477. doi: 10.1016/0149-7634(85)90022-3 PMID: 2999657
  12. Leyton, M.; Vezina, P. Dopamine ups and downs in vulnerability to addictions: A neurodevelopmental model. Trends Pharmacol. Sci., 2014, 35(6), 268-276. doi: 10.1016/j.tips.2014.04.002 PMID: 24794705
  13. Blum, K.; Raza, A.; Schultz, T.; Jalali, R.; Green, R.; Brewer, R.; Thanos, P.K.; McLaughlin, T.; Baron, D.; Bowirrat, A.; Elman, I.; Downs, B.W.; Bagchi, D.; Badgaiyan, R.D. Should we embrace the incorporation of genetically guided "dopamine homeostasis" in the treatment of REWARD DEFICIENCY SYNDROME (RSD) as a frontline therapeutic modality? Acta Sci Neurol., 2021, 4(2), 17-24. PMID: 33681869
  14. Gilley, E.D. Integrating the Science of Addiction and the Science of Wellbeing: 5 year update for the GAB21. The Global Conference on Addiction Medicine, Behavioral Health and Psychiatry, 2021, p. 65.
  15. Gilley, E. Re-conceptualizing Addiction: Integrating the Sciences of addiction medicine and Reward Deficiency Syndrome. The 2nd Edition Global Conference on Addiction Medicine, Behavioral Health and Psychiatry, 2021, p. 66.
  16. Blum, K.; Fried, L.; Madigan, M.A.; Giordano, J.; Modestino, E.J.; Steinberg, B.; Baron, D.; DeLeon, M.; McLaughlin, T.; Hauser, M.; Badgaiyan, R.D. Critical analysis of white house anti-drug plan. J. Rehabil. Med., 2017, 1(4), 555568. doi: 10.19080/GJARM.2017.01.555568 PMID: 29057394
  17. Columbia, C.A.S.A. Addiction medicine: Closing the gap between science and practice; Columbia University Press, 2012.
  18. Reese, E.D.; Kane, L.F.; Paquette, C.E.; Frohlich, F.; Daughters, S.B. Lost in translation: The gap between neurobiological mechanisms and psychosocial treatment research for substance use disorders. Curr. Addict. Rep., 2021, 8(3), 440-451. doi: 10.1007/s40429-021-00382-8
  19. Blum, K.; Wallace, J.E.; Briggs, A.H.; Trachtenberg, M.C. Evidence for the importance of the "genotype" theory in alcohol seeking behavior: A commentary. Alcohol Drug Res., 1985, 1986-1986 6(6), 455-461. PMID: 3015159
  20. Gilley, E.D. At the intersection of addiction and personality: Future directions for personality theory and research in the genomic era of medicine. European J. Biomed. Pharm. Sci., 2021, 8(9), 13-28.
  21. Gilley, E.D. Reconceptualizing addiction: Integrating the sciences of addiction and reward deficiency syndrome, Part 1. J. Addict., 2020, 4(1), 1-124.
  22. Blum, K.; Febo, M.; McLaughlin, T.; Cronjé, F.J.; Han, D.; Gold, M.S. Hatching the behavioral addiction egg: REWARD DEFICIENCY SOLUTION SYSTEM (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. J. Behav. Addict., 2014, 3(3), 149-156. doi: 10.1556/JBA.3.2014.019 PMID: 25317338
  23. Blum, K.; Bowirrat, A.; Lewis, M.C.G.; Simpatico, T.A.; Ceccanti, M.; Steinberg, B.; Modestino, E.J.; Thanos, P.K.; Baron, D.; McLaughlin, T.; Brewer, R.; Badgaiyan, R.D.; Ponce, J.V.; Lott, L.; Gold, M.S. Exploration of epigenetic state hyperdopaminergia (surfeit) and genetic trait hypodopaminergia (deficit) during adolescent brain development. Curr. Psychopharmacol., 2021, 10(3), 181-196. doi: 10.2174/2211556010666210215155509 PMID: 34707969
  24. Blum, K.; Kazmi, S.; Modestino, E.J.; Downs, B.W.; Bagchi, D.; Baron, D.; McLaughlin, T.; Green, R.; Jalali, R.; Thanos, P.K.; Elman, I.; Badgaiyan, R.D.; Bowirrat, A.; Gold, M.S. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating GENETIC ADDICTION RISK SEVERITY (GARS) and Dopamine Homeostasis Restoration. J. Pers. Med., 2021, 11(3), 212. doi: 10.3390/jpm11030212 PMID: 33809702
  25. Blum, K.; Badgaiyan, R.D. Translational and molecular cytoarchitectural genetic guided therapy to induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and associated drug and behavioral addiction seeking: A 60 year sojourn the future is now. EC Psycho Psychiatr, 2021, 10(8), 1-4. PMID: 34708222
  26. Blum, K.; Badgaiyan, R. REWARD DEFICIENCY SYNDROME (RDS): Entering the genomics and neuroscience era of addiction medicine. J. Reward Defic. Syndr. Addict. Sci., 2015, 1(1), 1-2.
  27. Blum, K.; Febo, M.; Badgaiyan, R.D.; Demetrovics, Z.; Simpatico, T.; Fahlke, C. M, O.B.; Li, M.; Dushaj, K.; Gold, M.S. Common Neurogenetic diagnosis and Meso Limbic manipulation of hypo-dopaminergic function in REWARD DEFICIENCY SYNDROME (RDS): Changing the recovery landscape. Curr. Neuropharmacol., 2017, 15(1), 184-194. doi: 10.2174/1570159X13666160512150918 PMID: 27174576
  28. Beitscher-Campbell, H.; Blum, K.; Febo, M.; Madigan, M.A.; Giordano, J.; Badgaiyan, R.D.; Braverman, E.R.; Dushaj, K.; Li, M.; Gold, M.S. Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. J. Behav. Addict., 2016, 5(3), 533-541. doi: 10.1556/2006.5.2016.055 PMID: 27502054
  29. Blumenthal, D.M.; Gold, M.S. Neurobiology of food addiction. Curr. Opin. Clin. Nutr. Metab. Care, 2010, 13(4), 359-365. doi: 10.1097/MCO.0b013e32833ad4d4 PMID: 20495452
  30. Blum, K.; Bowirrat, A.; Braverman, E.R.; Baron, D.; Cadet, J.L.; Kazmi, S.; Elman, I.; Thanos, P.K.; Badgaiyan, R.D.; Downs, W.B.; Bagchi, D.; Llanos-Gomez, L.; Gold, M.S. REWARD DEFICIENCY SYNDROME (RDS): A cytoarchitectural common neurobiological trait of all addictions. Int. J. Environ. Res. Public Health, 2021, 18(21), 11529. doi: 10.3390/ijerph182111529 PMID: 34770047
  31. Kotyuk, E.; Magi, A.; Eisinger, A.; Király, O.; Vereczkei, A.; Barta, C.; Griffiths, M.D.; Székely, A.; Kökönyei, G.; Farkas, J.; Kun, B.; Badgaiyan, R.D.; Urbán, R.; Blum, K.; Demetrovics, Z. Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the PSYCHOLOGICAL AND GENETIC FACTORS of the Addictive Behaviors (PGA) Study. J. Behav. Addict., 2020, 9(2), 272-288. doi: 10.1556/2006.2020.00033 PMID: 32609628
  32. Blum, K.; Morgan, J.; Cadet, J.L.; Baron, D.; Carney, P.R.; Khalsa, J.; Badgaiyan, R.D.; Gold, M.S. Psychoactive drugs like cannabis – induced hypodopaminergic anhedonia and neuropsychological dysfunction in humans: Putative induction of dopamine homeostasis via coupling of GENETIC ADDICTION RISK SEVERITY (GARS) testing and precision pro-dopamine regulation (KB220). Neurology, 2021, 13(4), 86-92. PMID: 34085060
  33. Robbins, T.W.; Ersche, K.D.; Everitt, B.J. Drug addiction and the memory systems of the brain. Ann. N. Y. Acad. Sci., 2008, 1141(1), 1-21. doi: 10.1196/annals.1441.020 PMID: 18991949
  34. Bowirrat, A.; Oscar-Berman, M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2005, 132B(1), 29-37. doi: 10.1002/ajmg.b.30080 PMID: 15457501
  35. Borsook, D.; Linnman, C.; Faria, V.; Strassman, A.M.; Becerra, L.; Elman, I. Reward deficiency and anti-reward in pain chronification. Neurosci. Biobehav. Rev., 2016, 68, 282-297. doi: 10.1016/j.neubiorev.2016.05.033 PMID: 27246519
  36. Linazaroso, G.; van Blercom, N.; Lasa, A. Hypothesis: Parkinson’s disease, reward deficiency syndrome and addictive effects of levodopa. Neurologia, 2004, 19(3), 117-127.
  37. Ferré, S. Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacology, 2016, 233(10), 1963-1979. doi: 10.1007/s00213-016-4212-2 PMID: 26786412
  38. Green, A.I.; Zimmet, S.V.; Straus, R.D.; Schildkraut, J.J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv. Rev. Psychiatry, 1999, 6(6), 287-296. doi: 10.3109/10673229909017206 PMID: 10370435
  39. Benton, D.; Young, H.A. A meta-analysis of the relationship between brain dopamine receptors and obesity: a matter of changes in behavior rather than food addiction? Int. J. Obes., 2016, 40(S1), S12-S21. doi: 10.1038/ijo.2016.9
  40. Kuss, D.J.; Pontes, H.M.; Griffiths, M.D. Neurobiological correlates in internet gaming disorder: A systematic literature review. Front. Psychiatry, 2018, 9, 166. doi: 10.3389/fpsyt.2018.00166 PMID: 29867599
  41. Hou, L.; Chang, L.; Chen, L.; Zhou, R. Reduced reward responsiveness in women with moderate - to - severe premenstrual syndrome: Evidence from a probabilistic reward task. Front. Psychiatry, 2020, 11, 28. doi: 10.3389/fpsyt.2020.00028 PMID: 32116845
  42. Gola, M.; Draps, M. Ventral striatal reactivity in compulsive sexual behaviors. Front. Psychiatry, 2018, 9, 546. doi: 10.3389/fpsyt.2018.00546 PMID: 30487759
  43. Alguacil, L.F.; González-Martín, C. Target identification and validation in brain reward dysfunction. Drug Discov. Today, 2015, 20(3), 347-352. doi: 10.1016/j.drudis.2014.10.014 PMID: 25541474
  44. Wolters, E.C.; van der Werf, Y.D.; van den Heuvel, O.A. Parkinson’s disease-related disorders in the impulsive-compulsive spectrum. J. Neurol., 2008, 255(Suppl. 5), 48-56. doi: 10.1007/s00415-008-5010-5 PMID: 18787882
  45. Elman, I.; Borsook, D.; Volkow, N.D. Pain and suicidality: Insights from reward and addiction neuroscience. Prog. Neurobiol., 2013, 109, 1-27. doi: 10.1016/j.pneurobio.2013.06.003 PMID: 23827972
  46. Lin, X.; Deng, J.; Shi, L.; Wang, Q.; Li, P.; Li, H.; Liu, J.; Que, J.; Chang, S.; Bao, Y.; Shi, J.; Weinberger, D.R.; Wu, P.; Lu, L. Neural substrates of smoking and reward cue reactivity in smokers: a meta-analysis of fMRI studies. Transl. Psychiatry, 2020, 10(1), 97. doi: 10.1038/s41398-020-0775-0 PMID: 32184386
  47. Doremus-Fitzwater, T.L.; Spear, L.P. Reward-centricity and attenuated aversions: An adolescent phenotype emerging from studies in laboratory animals. Neurosci. Biobehav. Rev., 2016, 70, 121-134. doi: 10.1016/j.neubiorev.2016.08.015 PMID: 27524639
  48. Maigaard, K.; Nejad, A.B.; Andersen, K.W.; Herz, D.M.; Hagstrøm, J.; Pagsberg, A.K.; Skov, L.; Siebner, H.R.; Plessen, K.J. A superior ability to suppress fast inappropriate responses in children with Tourette syndrome is further improved by prospect of reward. Neuropsychologia, 2019, 131, 342-352. doi: 10.1016/j.neuropsychologia.2019.05.012 PMID: 31103639
  49. Rovai, L.; Maremmani, A.G.; Pacini, M.; Pani, P.P.; Rugani, F.; Lamanna, F.; Schiavi, E.; Mautone, S.; Dell’Osso, L.; Maremmani, I. Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse. Riv. Psichiatr., 2013, 48(1), 1-9. doi: 10.1708/1228.13610 PMID: 23438696
  50. Mangge, H.; Summers, K.; Almer, G.; Prassl, R.; Weghuber, D.; Schnedl, W.; Fuchs, D. Antioxidant food supplements and obesity-related inflammation. Curr. Med. Chem., 2013, 20(18), 2330-2337. doi: 10.2174/0929867311320180004 PMID: 23531214
  51. Gyollai, A.; Griffiths, M.; Barta, C.; Vereczkei, A.; Urbán, R.; Kun, B.; Kökönyei, G.; Székely, A.; Sasvári-Székely, M.; Blum, K.; Demetrovics, Z. The genetics of problem and pathological gambling: a systematic review. Curr. Pharm. Des., 2014, 20(25), 3993-3999. doi: 10.2174/13816128113199990626 PMID: 24001288
  52. Manzardo, A.M.; Penick, E.C. A theoretical argument for inherited thiamine insensitivity as one possible biological cause of familial alcoholism. Alcohol. Clin. Exp. Res., 2006, 30(9), 1545-1550. doi: 10.1111/j.1530-0277.2006.00186.x PMID: 16930217
  53. Paelecke-Habermann, Y.; Paelecke, M.; Giegerich, K.; Reschke, K.; Kübler, A. Implicit and explicit reward learning in chronic nicotine use. Drug Alcohol Depend., 2013, 129(1-2), 8-17. doi: 10.1016/j.drugalcdep.2012.09.004 PMID: 23098679
  54. Paelecke-Habermann, Y.; Paelecke, M.; Mauth, J.; Tschisgale, J.; Lindenmeyer, J.; Kübler, A. A comparison of implicit and explicit reward learning in low risk alcohol users versus people who binge drink and people with alcohol dependence. Addict. Behav. Rep., 2019, 9, 100178. doi: 10.1016/j.abrep.2019.100178 PMID: 31193786
  55. Johnson, R.J.; Gold, M.S.; Johnson, D.R.; Ishimoto, T.; Lanaspa, M.A.; Zahniser, N.R.; Avena, N.M. Attention-deficit/hyperactivity disorder: is it time to reappraise the role of sugar consumption? Postgrad. Med., 2011, 123(5), 39-49. doi: 10.3810/pgm.2011.09.2458 PMID: 21904085
  56. Carroll, D.; Ginty, A.T.; Whittaker, A.C.; Lovallo, W.R.; de Rooij, S.R. The behavioural, cognitive, and neural corollaries of blunted cardiovascular and cortisol reactions to acute psychological stress. Neurosci. Biobehav. Rev., 2017, 77, 74-86. doi: 10.1016/j.neubiorev.2017.02.025 PMID: 28254428
  57. Maremmani, A.; Pacini, M.; Maremmani, I. What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients. Int. J. Environ. Res. Public Health, 2019, 16(3), 447. doi: 10.3390/ijerph16030447 PMID: 30717435
  58. McAllister, C.J.; Whittington, J.E.; Holland, A.J. Development of the eating behaviour in Prader–Willi Syndrome: advances in our understanding. Int. J. Obes., 2011, 35(2), 188-197. doi: 10.1038/ijo.2010.139 PMID: 20680019
  59. Kamarajan, C.; Rangaswamy, M.; Tang, Y.; Chorlian, D.B.; Pandey, A.K.; Roopesh, B.N.; Manz, N.; Saunders, R.; Stimus, A.T.; Porjesz, B. Dysfunctional reward processing in male alcoholics: An ERP study during a gambling task. J. Psychiatr. Res., 2010, 44(9), 576-590. doi: 10.1016/j.jpsychires.2009.11.019 PMID: 20035952
  60. Hahn, T.; Notebaert, K.H.; Dresler, T.; Kowarsch, L.; Reif, A.; Fallgatter, A.J. Linking online gaming and addictive behavior: converging evidence for a general reward deficiency in frequent online gamers. Front. Behav. Neurosci., 2014, 8, 385. doi: 10.3389/fnbeh.2014.00385 PMID: 25426039
  61. Oberlin, B.G.; Dzemidzic, M.; Bragulat, V.; Lehigh, C.A.; Talavage, T.; O’Connor, S.J.; Kareken, D.A. Limbic responses to reward cues correlate with antisocial trait density in heavy drinkers. Neuroimage, 2012, 60(1), 644-652. doi: 10.1016/j.neuroimage.2011.12.043 PMID: 22227139
  62. Verbeken, S.; Braet, C.; Lammertyn, J.; Goossens, L.; Moens, E. How is reward sensitivity related to bodyweight in children? Appetite, 2012, 58(2), 478-483. doi: 10.1016/j.appet.2011.11.018 PMID: 22138702
  63. Davis, C.; Fox, J. Sensitivity to reward and body mass index (BMI): Evidence for a non-linear relationship. Appetite, 2008, 50(1), 43-49. doi: 10.1016/j.appet.2007.05.007 PMID: 17614159
  64. Harb, M.R.; Almeida, O.F.X. Altered motivation masks appetitive learning potential of obese mice. Front. Behav. Neurosci., 2014, 8, 377. doi: 10.3389/fnbeh.2014.00377 PMID: 25400563
  65. Davis, C.; Levitan, R.D.; Kaplan, A.S.; Carter, J.; Reid, C.; Curtis, C.; Patte, K.; Hwang, R.; Kennedy, J.L. Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(3), 620-628. doi: 10.1016/j.pnpbp.2007.09.024 PMID: 18262320
  66. Rahman, N.; Mihalkovic, A.; Geary, O.; Haffey, R.; Hamilton, J.; Thanos, P.K. Chronic aerobic exercise: Autoradiographic assessment of GABA(a) and mu-opioid receptor binding in adult rats. Pharmacol. Biochem. Behav., 2020, 196, 172980. doi: 10.1016/j.pbb.2020.172980 PMID: 32593790
  67. Nestor, L.; Hester, R.; Garavan, H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage, 2010, 49(1), 1133-1143. doi: 10.1016/j.neuroimage.2009.07.022 PMID: 19631753
  68. Gerra, M.C.; Manfredini, M.; Cortese, E.; Antonioni, M.C.; Leonardi, C.; Magnelli, F.; Somaini, L.; Jayanthi, S.; Cadet, J.L.; Donnini, C. Genetic and environmental risk factors for cannabis Use: Preliminary results for the role of parental care perception. Subst. Use Misuse, 2019, 54(4), 670-680. doi: 10.1080/10826084.2018.1531430 PMID: 30663487
  69. Wu, C.; Garamszegi, S.P.; Xie, X.; Mash, D.C. Altered dopamine synaptic markers in postmortem brain of obese subjects. Front. Hum. Neurosci., 2017, 11, 386. doi: 10.3389/fnhum.2017.00386 PMID: 28824395
  70. Rothman, R.B.; Blough, B.E.; Baumann, M.H. Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions. AAPS J., 2007, 9(1), E1-E10. doi: 10.1208/aapsj0901001 PMID: 17408232
  71. Rivas-Grajales, A.M.; Sawyer, K.S.; Karmacharya, S.; Papadimitriou, G.; Camprodon, J.A.; Harris, G.J.; Kubicki, M.; Oscar-Berman, M.; Makris, N. Sexually dimorphic structural abnormalities in major connections of the medial forebrain bundle in alcoholism. Neuroimage Clin., 2018, 19, 98-105. doi: 10.1016/j.nicl.2018.03.025 PMID: 30035007
  72. Lazaratou, H.; Palaiologou, A.; Anagnostopoulos, D. Impulsivity as an immediate factor between addictive disorders and Attention Deficit-Hyperactivity Disorder. Psychiatriki, 2017, 28(2), 156-164. doi: 10.22365/jpsych.2017.282.156
  73. Fronczek, R.; Schinkelshoek, M.; Shan, L.; Lammers, G.J. The orexin/hypocretin system in neuropsychiatric disorders: Relation to signs and symptoms. Handb. Clin. Neurol., 2021, 180, 343-358. doi: 10.1016/B978-0-12-820107-7.00021-5 PMID: 34225940
  74. Kononoff Vanhanen, J.; Nuutinen, S.; Tuominen, M.; Panula, P. Histamine H3 receptor regulates sensorimotor gating and dopaminergic signaling in the striatum. J. Pharmacol. Exp. Ther., 2016, 357(2), 264-272. doi: 10.1124/jpet.115.230771 PMID: 26945087
  75. Kim, M.; Custodio, R.J.; Botanas, C.J.; de la Peña, J.B.; Sayson, L.V.; Abiero, A.; Ryoo, Z.Y.; Cheong, J.H.; Kim, H.J. The circadian gene, Per2, influences methamphetamine sensitization and reward through the dopaminergic system in the striatum of mice. Addict. Biol., 2019, 24(5), 946-957. doi: 10.1111/adb.12663 PMID: 30091820
  76. Suzuki, H.; Han, S.D.; Lucas, L.R. Chronic passive exposure to aggression decreases D2 and 5-HT1B receptor densities. Physiol. Behav., 2010, 99(5), 562-570. doi: 10.1016/j.physbeh.2010.01.018 PMID: 20114057
  77. Ananth, M.; Hetelekides, E.M.; Hamilton, J.; Thanos, P.K. Dopamine D4 receptor gene expression plays important role in extinction and reinstatement of cocaine-seeking behavior in mice. Behav. Brain Res., 2019, 365, 1-6. doi: 10.1016/j.bbr.2019.02.036 PMID: 30797855
  78. Shukla, A.; Beroun, A.; Panopoulou, M.; Neumann, P.A.; Grant, S.G.N.; Olive, M.F.; Dong, Y.; Schlüter, O.M. Calcium‐permeable AMPA receptors and silent synapses in cocaine‐conditioned place preference. EMBO J., 2017, 36(4), 458-474. doi: 10.15252/embj.201695465 PMID: 28077487
  79. Hamilton, J.; Swenson, S.; Hajnal, A.; Thanos, P.K. Roux-en-Y gastric bypass surgery normalizes dopamine D1, D2, and DAT levels. Synapse, 2018, 72(10), e22058. Epub ahead of print doi: 10.1002/syn.22058 PMID: 29992624
  80. Kosillo, P.; Bateup, H.S. Dopaminergic dysregulation in syndromic autism spectrum disorders: Insights from genetic mouse models. Front. Neural Circuits, 2021, 15, 700968. doi: 10.3389/fncir.2021.700968 PMID: 34366796
  81. Althaus, M.; Groen, Y.; Wijers, A.A.; Mulder, L.J.M.; Minderaa, R.B.; Kema, I.P.; Dijck, J.D.A.; Hartman, C.A.; Hoekstra, P.J. Differential effects of 5-HTTLPR and DRD2/ANKK1 polymorphisms on electrocortical measures of error and feedback processing in children. Clin. Neurophysiol., 2009, 120(1), 93-107. doi: 10.1016/j.clinph.2008.10.012 PMID: 19046929
  82. Figueiredo, A.; Hamilton, J.; Marion, M.; Blum, K.; Kaczocha, M.; Haj-Dahmane, S.; Deutsch, D.; Thanos, P.K. Pharmacological inhibition of brain fatty acid binding protein reduces ethanol consumption in mice. J. Reward Defic. Syndr. Addict. Sci., 2017, 3(2), 21-27. doi: 10.17756/jrdsas.2017-037 PMID: 29367955
  83. Cui, Y.; Ostlund, S.B.; James, A.S.; Park, C.S.; Ge, W.; Roberts, K.W.; Mittal, N.; Murphy, N.P.; Cepeda, C.; Kieffer, B.L.; Levine, M.S.; Jentsch, J.D.; Walwyn, W.M.; Sun, Y.E.; Evans, C.J.; Maidment, N.T.; Yang, X.W. Targeted expression of µ-opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward. Nat. Neurosci., 2014, 17(2), 254-261. doi: 10.1038/nn.3622 PMID: 24413699
  84. Ponce, G.; Jimenez-Arriero, M.A.; Rubio, G.; Hoenicka, J.; Ampuero, I.; Ramos, J.A.; Palomo, T. The A1 allele of the DRD2 gene (TaqI A polymorphisms) is associated with antisocial personality in a sample of alcohol-dependent patients. Eur. Psychiatry, 2003, 18(7), 356-360. doi: 10.1016/j.eurpsy.2003.06.006 PMID: 14643564
  85. Porat, O.; Hassin-Baer, S.; Cohen, O.S.; Markus, A.; Tomer, R. Asymmetric dopamine loss differentially affects effort to maximize gain or minimize loss. Cortex, 2014, 51, 82-91. doi: 10.1016/j.cortex.2013.10.004 PMID: 24267688
  86. Robison, L.S.; Ananth, M.; Hadjiargyrou, M.; Komatsu, D.E.; Thanos, P.K. Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats. J. Neural Transm., 2017, 124(5), 655-667. doi: 10.1007/s00702-017-1680-4 PMID: 28116523
  87. Obici, S.; Magrisso, I.J.; Ghazarian, A.S.; Shirazian, A.; Miller, J.R.; Loyd, C.M.; Begg, D.P.; Krawczewski Carhuatanta, K.A.; Haas, M.K.; Davis, J.F.; Woods, S.C.; Sandoval, D.A.; Seeley, R.J.; Goodyear, L.J.; Pothos, E.N.; Mul, J.D. Moderate voluntary exercise attenuates the metabolic syndrome in melanocortin-4 receptor-deficient rats showing central dopaminergic dysregulation. Mol. Metab., 2015, 4(10), 692-705. doi: 10.1016/j.molmet.2015.07.003 PMID: 26500841
  88. Castañé, A.; Robledo, P.; Matifas, A.; Kieffer, B.L.; Maldonado, R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur. J. Neurosci., 2003, 17(1), 155-159. doi: 10.1046/j.1460-9568.2003.02409.x PMID: 12534979
  89. Trigo, J.M.; Zimmer, A.; Maldonado, R. Nicotine anxiogenic and rewarding effects are decreased in mice lacking β-endorphin. Neuropharmacology, 2009, 56(8), 1147-1153. doi: 10.1016/j.neuropharm.2009.03.013 PMID: 19376143
  90. Contarino, A.; Kitchener, P.; Vallée, M.; Papaleo, F.; Piazza, P.V. CRF1 receptor-deficiency increases cocaine reward. Neuropharmacology, 2017, 117, 41-48. doi: 10.1016/j.neuropharm.2017.01.024 PMID: 28137450
  91. Hommer, D.W.; Bjork, J.M.; Gilman, J.M. Imaging brain response to reward in addictive disorders. Ann. N. Y. Acad. Sci., 2011, 1216(1), 50-61. doi: 10.1111/j.1749-6632.2010.05898.x PMID: 21272010
  92. Koob, G.F.; Le Moal, M. Addiction and the brain antireward system. Annu. Rev. Psychol., 2008, 59(1), 29-53. doi: 10.1146/annurev.psych.59.103006.093548 PMID: 18154498
  93. Chang, Y.; Wang, Y.; Mei, S.; Yi, W.; Zheng, Y. Blunted neural effects of perceived control on reward feedback in major depressive disorder. J. Affect. Disord., 2020, 276, 112-118. doi: 10.1016/j.jad.2020.06.071 PMID: 32697689
  94. Cador, M.; Taylor, J.R.; Robbins, T.W. Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens. Psychopharmacology, 1991, 104(3), 377-385. doi: 10.1007/BF02246039 PMID: 1924645
  95. Shen, H.; Chen, K.; Marino, R.A.M.; McDevitt, R.A.; Xi, Z.X. Deletion of VGLUT2 in midbrain dopamine neurons attenuates dopamine and glutamate responses to methamphetamine in mice. Pharmacol. Biochem. Behav., 2021, 202, 173104. doi: 10.1016/j.pbb.2021.173104 PMID: 33444596
  96. Blaker, A.L.; Moore, E.R.; Yamamoto, B.K. Serial exposure to ethanol drinking and methamphetamine enhances glutamate excitotoxicity. J. Neurochem., 2019, 151(6), 749-763. doi: 10.1111/jnc.14861 PMID: 31478210
  97. Cléry-Melin, M.L.; Jollant, F.; Gorwood, P. Reward systems and cognitions in Major Depressive Disorder. CNS Spectr., 2019, 24(1), 64-77. doi: 10.1017/S1092852918001335 PMID: 30472971
  98. Althobaiti, Y.S.; Almutairi, F.M.; Alshehri, F.S.; Altowairqi, E.; Marghalani, A.M.; Alghorabi, A.A.; Alsanie, W.F.; Gaber, A.; Alsaab, H.O.; Almalki, A.H.; Hakami, A.Y.; Alkhalifa, T.; Almalki, A.D.; Hardy, A.M.G.; Shah, Z.A. Involvement of the dopaminergic system in the reward-related behavior of pregabalin. Sci. Rep., 2021, 11(1), 10577. doi: 10.1038/s41598-021-88429-8 PMID: 34011976
  99. Tata, D.A.; Yamamoto, B.K. Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction, 2007, 102(Suppl. 1), 49-60. doi: 10.1111/j.1360-0443.2007.01770.x PMID: 17493053
  100. Stephans, S.E.; Yamamoto, B.K. Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux. Synapse, 1994, 17(3), 203-209. doi: 10.1002/syn.890170310 PMID: 7974204
  101. Stephans, S.E.; Yamamoto, B.K. Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex. Brain Res., 1995, 700(1-2), 99-106. doi: 10.1016/0006-8993(95)00938-M PMID: 8624733
  102. Kumar, P.; Goer, F.; Murray, L.; Dillon, D.G.; Beltzer, M.L.; Cohen, A.L.; Brooks, N.H.; Pizzagalli, D.A. Impaired reward prediction error encoding and striatal-midbrain connectivity in depression. Neuropsychopharmacology, 2018, 43(7), 1581-1588. doi: 10.1038/s41386-018-0032-x PMID: 29540863
  103. Badgaiyan, R.D.; Sinha, S.; Sajjad, M.; Wack, D.S. Attenuated tonic and enhanced phasic release of dopamine in attention deficit hyperactivity disorder. PLoS One, 2015, 10(9), e0137326. doi: 10.1371/journal.pone.0137326 PMID: 26422146
  104. Blum, K.; Thanos, P.; Oscar-Berman, M.; Febo, M.; Baron, D.; Badgaiyan, R.D.; Gardner, E.; Demetrovics, Z.; Fahlke, C.; Haberstick, B.C.; Dushaj, K.; Gold, M.S. Dopamine in the brain: Hypothesizing surfeit or deficit links to reward and addiction. J. Reward Defic. Syndr., 2015, 1(3), 95-104. doi: 10.17756/jrds.2015-016 PMID: 27398406
  105. Nutt, D.J.; Lingford-Hughes, A.; Erritzoe, D.; Stokes, P.R.A. The dopamine theory of addiction: 40 years of highs and lows. Nat. Rev. Neurosci., 2015, 16(5), 305-312. doi: 10.1038/nrn3939 PMID: 25873042
  106. Blum, K.; Febo, M.; Fried, L.; Li, M.; Dushaj, K.; Braverman, E.R.; McLaughlin, T.; Steinberg, B.; Badgaiyan, R.D. Hypothesizing that neuropharmacological and neuroimaging studies of glutaminergic-dopaminergic optimization complex (KB220Z) are associated with "Dopamine homeostasis" in reward deficiency syndrome (RDS). Subst. Use Misuse, 2017, 52(4), 535-547. doi: 10.1080/10826084.2016.1244551 PMID: 28033474
  107. Dackis, C.A.; Gold, M.S.; Davies, R.K.; Sweeney, D.R. Bromocriptine treatment for cocaine abuse: the dopamine depletion hypothesis. Int. J. Psychiatry Med., 1986-1986-1986, 15(2), 125-135. doi: 10.2190/GXPA-98AK-4RR4-HD9B PMID: 3902694
  108. Willuhn, I.; Burgeno, L.M.; Groblewski, P.A.; Phillips, P.E.M. Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. Nat. Neurosci., 2014, 17(5), 704-709. doi: 10.1038/nn.3694 PMID: 24705184
  109. Borsini, A.; Wallis, A.S.J.; Zunszain, P.; Pariante, C.M.; Kempton, M.J. Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression. Cogn. Affect. Behav. Neurosci., 2020, 20(4), 816-841. doi: 10.3758/s13415-020-00804-6 PMID: 32472419
  110. Madrid, G.A.; MacMurray, J.; Lee, J.W.; Anderson, B.A.; Comings, D.E. Stress as a mediating factor in the association between the DRD2 TaqI polymorphism and alcoholism. Alcohol, 2001, 23(2), 117-122. doi: 10.1016/S0741-8329(00)00138-5 PMID: 11331109
  111. Kótyuk, E.; Urbán, R.; Hende, B.; Richman, M.; Magi, A.; Király, O.; Barta, C.; Griffiths, M.D.; Potenza, M.N.; Badgaiyan, R.D.; Blum, K.; Demetrovics, Z. Development and validation of the REWARD DEFICIENCY SYNDROME QUESTIONNAIRE (RDSQ-29). J. Psychopharmacol., 2022, 36(3), 409-422. doi: 10.1177/02698811211069102 PMID: 35102768
  112. Enoch, M.A. The influence of gene-environment interactions on the development of alcoholism and drug dependence. Curr. Psychiatry Rep., 2012, 14(2), 150-158. doi: 10.1007/s11920-011-0252-9 PMID: 22367454
  113. Gold, M.S.; Blum, K.; Oscar-Berman, M.; Braverman, E.R. Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children? Postgrad. Med., 2014, 126(1), 153-177. doi: 10.3810/pgm.2014.01.2735 PMID: 24393762
  114. Gilley, E. The new science of attention deficit hyperactivity disorder: News from the cutting edge of research science. Journal of Psychiatry and Psychiatric Disorders, 2018, 2(3), 71-76. b doi: 10.26502/jppd.2572-519X0043
  115. Archer, T.; Oscar Berman, M.; Blum, K. Epigenetics in developmental disorder. ADHD and Endophenotypes. J. Genet. Syndr. Gene Ther., 2011, 2(1), 1-33. doi: 10.4172/2157-7412.1000104 PMID: 22224195
  116. Blum, K.; Baron, D.; Lott, L.; Ponce, V.; Siwicki, D. In search of REWARD DEFICIENCY SYNDROME (RDS)-Free Controls: The Holy Grail in genetic addiction risk testing. Curr. Psychopharmacol., 2019, 8, 1-15. PMID: 32432025
  117. Gilley, E.D. A proposed treatment plan model for Reward Deficiency Syndrome: To help in restructuring the addiction recovery industry. European J. Biomed. Pharm. Sci., 2018, 5(11), 84-90.
  118. Blum, K.; Oscar-Berman, M.; Jacobs, W.; McLaughlin, T.; Gold, M.S. Buprenorphine response as a function of neurogenetic polymorphic antecedents: Can dopamine genes affect clinical outcomes in REWARD DEFICIENCY SYNDROME (RDS). J. Addict. Res. Ther., 2014, 5(3), 1000185. doi: 10.4172/2155-6105.1000185 PMID: 25664200
  119. Moran, M.; Blum, K.; Ponce, J.V.; Lott, L.; Gondré-Lewis, M.C.; Badgaiyan, S.; Brewer, R.; Downs, B.W.; Fynman, P.; Weingarten, A.; Cadet, J.L.; Smith, D.E.; Baron, D.; Thanos, P.K.; Modestino, E.J.; Badgaiyan, R.D.; Elman, I.; Gold, M.S. High Genetic Addiction Risk Score (GARS) in chronically prescribed severe chronic opioid probands attending multi-pain clinics: An open clinical pilot trial. Mol. Neurobiol., 2021, 58(7), 3335-3346. doi: 10.1007/s12035-021-02312-1 PMID: 33683627
  120. Fried, L.; Modestino, E.J.; Siwicki, D.; Lott, L.; Thanos, P.K.; Baron, D.; Badgaiyan, R.D.; Ponce, J.V.; Giordano, J.; Downs, W.B.; Gondré-Lewis, M.C.; Bruce, S.; Braverman, E.R.; Boyett, B.; Blum, K. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a generational family affair. Curr. Pharm. Biotechnol., 2020, 21(6), 528-541. doi: 10.2174/1389201021666191210112108 PMID: 31820688
  121. Noble, E.P.; Blum, K.; Ritchie, T.; Montgomery, A.; Sheridan, P.J. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry, 1991, 48(7), 648-654. doi: 10.1001/archpsyc.1991.01810310066012 PMID: 2069496
  122. Jiang, Y.; Liu, B.; Wu, C.; Gao, X.; Lu, Y.; Lian, Y.; Liu, J. Dopamine receptor D2 gene (DRD2) polymorphisms, job stress, and their interaction on sleep dysfunction. Int. J. Environ. Res. Public Health, 2020, 17(21), 8174. doi: 10.3390/ijerph17218174 PMID: 33167416
  123. Jönsson, E.G.; Nöthen, M.M.; Grünhage, F.; Farde, L.; Nakashima, Y.; Propping, P.; Sedvall, G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry, 1999, 4(3), 290-296. doi: 10.1038/sj.mp.4000532 PMID: 10395223
  124. Hirvonen, M.M.; Lumme, V.; Hirvonen, J.; Pesonen, U.; Någren, K.; Vahlberg, T.; Scheinin, H.; Hietala, J. C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(4), 630-636. doi: 10.1016/j.pnpbp.2009.02.021 PMID: 19285111
  125. Blum, K.; Baron, D.; McLaughlin, T.; Gold, M.S. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to ENDORPHINERGIC DEFICIENCY SYNDROME (EDS). J. Neurol. Sci., 2020, 411, 116733. doi: 10.1016/j.jns.2020.116733 PMID: 32088516
  126. Hillemacher, T.; Frieling, H.; Buchholz, V.; Hussein, R.; Bleich, S.; Meyer, C.; John, U.; Bischof, A. Rumpf, HJ Alterations in DNA-methylation of the dopamine-receptor 2 gene are associated with abstinence and health care utilization in individuals with a lifetime history of pathologic gambling. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015, 63, 30-34. doi: 10.1016/j.pnpbp.2015.05.013
  127. Linnet, J. The anticipatory dopamine response in addiction: A common neurobiological underpinning of gambling disorder and substance use disorder? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019. doi: 10.1016/j.pnpbp.2019.109802 PMID: 31678482
  128. Gold, M.S.; Baron, D.; Bowirrat, A.; Blum, K. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? J. Neurol. Sci., 2020, 418, 117137. doi: 10.1016/j.jns.2020.117137 PMID: 32957037
  129. Gilley, E.D. Reward deficiency syndrome solution focused brief therapy to begin integrating the sciences of addiction & reward deficiency syndrome (RDS). J. Reward Defic. Syndr. Addict. Sci., 2019, 5(1), 1-6. doi: 10.17756/jrdsas.2019-042
  130. Miller, M.; Chen, A.L.C.; Stokes, S.D.; Silverman, S.; Bowirrat, A.; Manka, M.; Manka, D.; Miller, D.K.; Perrine, K.; Chen, T.J.H.; Bailey, J.A.; Downs, W.; Waite, R.L.; Madigan, M.A.; Braverman, E.R.; Damle, U.; Kerner, M.; Giordano, J.; Morse, S.; Oscar-Berman, M.; Barh, D.; Blum, K. Early intervention of intravenous KB220IV-neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study. J. Psychoactive Drugs, 2012, 44(5), 398-409. doi: 10.1080/02791072.2012.737727 PMID: 23457891
  131. Blum, K.; Chen, T.J.H.; Downs, B.W.; Bowirrat, A.; Waite, R.L.; Braverman, E.R.; Madigan, M.; Oscar-Berman, M.; DiNubile, N.; Stice, E.; Giordano, J.; Morse, S.; Gold, M. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "DEPRIVATION-AMPLIFICATION RELAPSE THERAPY" (DART). Postgrad. Med., 2009, 121(6), 176-196. doi: 10.3810/pgm.2009.11.2087 PMID: 19940429
  132. Blum, K.; Khalsa, J.; Cadet, J.L.; Baron, D.; Bowirrat, A.; Boyett, B.; Lott, L.; Brewer, R.; Gondré-Lewis, M.; Bunt, G.; Kazmi, S. Gold, M.S. -Induced hypodopaminergic anhedonia and cognitive decline in humans: Embracing putative induction of dopamine homeostasis. Front. Psychiatry, 2021, 12, 623403. doi: 10.3389/fpsyt.2021.623403 PMID: 33868044
  133. Weiland, B.J.; Zucker, R.A.; Zubieta, J.K.; Heitzeg, M.M. Striatal dopaminergic reward response relates to age of first drunkenness and feedback response in at-risk youth. Addict. Biol., 2017, 22(2), 502-512. doi: 10.1111/adb.12341 PMID: 26732626
  134. Thompson, L.L.; Claus, E.D.; Mikulich-Gilbertson, S.K.; Banich, M.T.; Crowley, T.; Krmpotich, T.; Miller, D.; Tanabe, J. Negative reinforcement learning is affected in substance dependence. Drug Alcohol Depend., 2012, 123(1-3), 84-90. doi: 10.1016/j.drugalcdep.2011.10.017 PMID: 22079143
  135. Tooby, J.; Cosmides, L. On the universality of human nature and the uniqueness of the individual: The role of genetics and adaptation. J. Pers., 1990, 58(1), 17-67. doi: 10.1111/j.1467-6494.1990.tb00907.x PMID: 2198338
  136. Karimpour-Vazifehkhorani, A.; Bakhshipour Rudsari, A.; Rezvanizadeh, A. Kehtary- Harzang, L.; Hasanzadeh, K. Behavioral activation, therapy on reward seeking behaviors in depressed people: An experimental study. J. Caring Sci., 2020, 9(4), 195-202. doi: 10.34172/jcs.2020.030 PMID: 33409163
  137. Cunningham, S.; Mazurka, R.; Wynne-Edwards, K.E.; Milev, R.V.; Pizzagalli, D.A.; Kennedy, S.; Harkness, K.L. Cortisol reactivity to stress predicts behavioral responsivity to reward moderation by sex, depression, and anhedonia. J. Affect. Disord., 2021, 293, 1-8. doi: 10.1016/j.jad.2021.05.126 PMID: 34153656
  138. Kalivas, P.W.; O’Brien, C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology, 2008, 33(1), 166-180. doi: 10.1038/sj.npp.1301564 PMID: 17805308
  139. Gilley, E.D. The evolution of addiction treatment: The disease is reward deficiency syndrome (RDS) and Addiction is its symptom. European J. Biomed. Pharm. Sci., 2018, 5(1), 161-166.
  140. Saddoris, M.P.; Wang, X.; Sugam, J.A.; Carelli, R.M. Cocaine self-administration experience induces pathological phasic accumbens dopamine signals and abnormal incentive behaviors in drug-abstinent rats. J. Neurosci., 2016, 36(1), 235-250. doi: 10.1523/JNEUROSCI.3468-15.2016 PMID: 26740664
  141. Owesson-White, C.A.; Ariansen, J.; Stuber, G.D.; Cleaveland, N.A.; Cheer, J.F.; Mark Wightman, R.; Carelli, R.M. Neural encoding of cocaine-seeking behavior is coincident with phasic dopamine release in the accumbens core and shell. Eur. J. Neurosci., 2009, 30(6), 1117-1127. doi: 10.1111/j.1460-9568.2009.06916.x PMID: 19735286
  142. Blum, K.; Downs, B.W.; Dushaj, K.; Li, M.; Braverman, E.R.; Fried, L.; Waite, R.; Demotrovics, Z.; Badgaiyan, R.D. The benefits of customized DNA directed nutrition to balance the brain reward circuitry and reduce addictive behaviors. Precis. Med., 2016, 1(1), 18-33. PMID: 28066828
  143. Blum, K.; Modestino, E.J.; Gondre-Lewis, M.C.; Baron, D.; Steinberg, B.; Thanos, P.; Downs, W.; Siwicki, D.; Lott, L.; Braverman, E.; Moran, M.; Miller, D.; Fried, L.; Bedgaiyan, R. Pro-dopamine regulator (KB220) a fifty year sojourn to combat reward deficiency syndrome (RDS): Evidence based bibliography (Annotated). Addict. Biol., 2018, 1(2), 1-26.
  144. Gunderson, J.G. Commentary on "Personality traits and the classification of mental disorders: Toward a more complete integration in DSM-5 and an empirical model of psychopathology". Pers. Disord., 2010, 1(2), 119-122. doi: 10.1037/a0019974
  145. Blinkhorn, S.; Johnson, C. The insignificance of personality testing. Nature, 1990, 348(6303), 671-672. doi: 10.1038/348671a0
  146. Baumeister, R.F.; Tice, D.M. Rethinking and reclaiming the interdisciplinary role of personality psychology: The science of human nature should be the center of the social sciences and humanities. J. Res. Pers., 1996, 30(3), 363-373. doi: 10.1006/jrpe.1996.0025
  147. Swenson, S.; Blum, K.; McLaughlin, T.; Gold, M.S.; Thanos, P.K. The therapeutic potential of exercise for neuropsychiatric diseases: A review. J. Neurol. Sci., 2020, 412, 116763. doi: 10.1016/j.jns.2020.116763 PMID: 32305746
  148. Kjaer, T.W.; Bertelsen, C.; Piccini, P.; Brooks, D.; Alving, J.; Lou, H.C. Increased dopamine tone during meditation-induced change of consciousness. Brain Res. Cogn. Brain Res., 2002, 13(2), 255-259. doi: 10.1016/S0926-6410(01)00106-9 PMID: 11958969
  149. Beraldo, L.; Gil, F.; Ventriglio, A.; de Andrade, A.G.; da Silva, A.G.; Torales, J.; Gonçalves, P.D.; Bhugra, D.; Castaldelli-Maia, J.M. Spirituality, religiosity and addiction recovery: Current perspectives. Curr. Drug Res. Rev., 2019, 11(1), 26-32. doi: 10.2174/1874473711666180612075954 PMID: 29895258
  150. Schoenthaler, S.J.; Blum, K.; Braverman, E.R.; Giordano, J.; Thompson, B.; Oscar-Berman, M.; Badgaiyan, R.D.; Madigan, M.A.; Dushaj, K.; Li, M.; Demotrovics, Z.; Waite, R.L.; Gold, M.S. NIDA-drug addiction treatment outcome study (DATOS) relapse as a function of spirituality/religiosity. J. Reward Defic. Syndr., 2015, 1(1), 36-45. doi: 10.17756/jrds.2015-007 PMID: 26052556
  151. Jayawickreme, E.; Forgeard, M.J.C.; Seligman, M.E.P. The engine of well-being. Rev. Gen. Psychol., 2012, 16(4), 327-342. doi: 10.1037/a0027990
  152. Krentzman, A.R. Review of the application of positive psychology to substance use, addiction, and recovery research. Psychol. Addict. Behav., 2013, 27(1), 151-165. doi: 10.1037/a0029897 PMID: 22985057
  153. Kobau, R.; Seligman, C.; Peterson, C.; Diener, E.; Zack, W.; Chapman, D. Mental health promotion in public health: Perspectives and strategies from positive psychology. American Journal of Public Health, 2011, 101(8), el-e9. doi: 10.2105/AJPH.2010.300083
  154. Hoge, E.A.; Bui, E.; Marques, L.; Metcalf, C.A.; Morris, L.K.; Robinaugh, D.J.; Worthington, J.J.; Pollack, M.H.; Simon, N.M. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: Effects on anxiety and stress reactivity. J. Clin. Psychiatry, 2013, 74(8), 786-792. doi: 10.4088/JCP.12m08083 PMID: 23541163
  155. Flanagan, O. The shame of addiction. Front. Psychiatry, 2013, 4, 120. doi: 10.3389/fpsyt.2013.00120 PMID: 24115936
  156. Judge, T.A.; Bono, J.E. Relationship of core self-evaluations traits—self-esteem, generalized self-efficacy, locus of control, and emotional stability—with job satisfaction and job performance: A meta-analysis. J. Appl. Psychol., 2001, 86(1), 80-92. doi: 10.1037/0021-9010.86.1.80 PMID: 11302235
  157. Abijo, T.; Blum, K.; Gondré-Lewis, M.C. Neuropharmacological and neurogenetic correlates of opioid use disorder (OUD) as a function of ethnicity: Relevance to precision addiction medicine. Curr. Neuropharmacol., 2020, 18(7), 578-595. doi: 10.2174/1570159X17666191118125702 PMID: 31744450
  158. Blum, K.; Modestino, E.J.; Neary, J.; Gondré-Lewis, M.C.; Siwicki, D.; Moran, M.; Hauser, M.; Braverman, E.R.; Baron, D.; Steinberg, B.; Laughlin, T.M. Badgaiyan, RD promoting PRECISION ADDICTION MANAGEMENT (PAM) to Combat the Global Opioid Crisis. Biomed. J. Sci. Tech. Res., 2018, 2(2), 1-4. doi: 10.26717/BJSTR.2018.02.000738
  159. Balconi, M.; Finocchiaro, R. Decisional impairments in cocaine addiction, reward bias, and cortical oscillation "unbalance". Neuropsychiatr. Dis. Treat., 2015, 11, 777-786. doi: 10.2147/NDT.S79696 PMID: 25848274
  160. Kuhlemeier, A.; Desai, Y.; Tonigan, A.; Witkiewitz, K.; Jaki, T.; Hsiao, Y.Y.; Chang, C.; Van Horn, M.L. Applying methods for personalized medicine to the treatment of alcohol use disorder. J. Consult. Clin. Psychol., 2021, 89(4), 288-300. doi: 10.1037/ccp0000634 PMID: 34014691
  161. Blum, K.; Han, D.; Hauser, M.; Downs, B.; Giordano, J. Neurogenetic impairments of brain reward circuitry links to reward deficiency syndrome (RDS) as evidenced by genetic addiction risk score (GARS): A case study. IIOAB J., 2013, 4, 4-9.
  162. South, S. Hamrick’s, S. Personality disorders: Toward theoretical and empirical integration in diagnosis and assessment; American Psychological Association, 2015, pp. 163-201.
  163. Casey, K.F.; Benkelfat, C.; Cherkasova, M.V.; Baker, G.B.; Dagher, A.; Leyton, M. Reduced dopamine response to amphetamine in subjects at ultra-high risk for addiction. Biol. Psychiatry, 2014, 76(1), 23-30. doi: 10.1016/j.biopsych.2013.08.033 PMID: 24138922
  164. Blum, K.; Gondré-Lewis, M.C.; Modestino, E.J.; Lott, L.; Baron, D.; Siwicki, D.; McLaughlin, T.; Howeedy, A.; Krengel, M.H.; Oscar-Berman, M.; Thanos, P.K.; Elman, I.; Hauser, M.; Fried, L.; Bowirrat, A.; Badgaiyan, R.D. Understanding the scientific basis of POST-TRAUMATIC STRESS DISORDER (PTSD): Precision behavioral management overrides stigmatization. Mol. Neurobiol., 2019, 56(11), 7836-7850. doi: 10.1007/s12035-019-1600-8 PMID: 31124077
  165. Blum, K.; Gold, M.S.; Llanos-Gomez, L.; Jalali, R.; Thanos, P.K.; Bowirrat, A.; Downs, W.B.; Bagchi, D.; Braverman, E.R.; Baron, D.; Roy, A.K., III; Badgaiyan, R.D. Hypothesizing nutrigenomic-based precision anti-obesity treatment and prophylaxis: Should we be targeting sarcopenia induced brain dysfunction? Int. J. Environ. Res. Public Health, 2021, 18(18), 9774. doi: 10.3390/ijerph18189774 PMID: 34574696
  166. Blum, K.; Chen, A.L.C.; Oscar-Berman, M.; Chen, T.J.H.; Lubar, J.; White, N.; Lubar, J.; Bowirrat, A.; Braverman, E.; Schoolfield, J.; Waite, R.L.; Downs, B.W.; Madigan, M.; Comings, D.E.; Davis, C.; Kerner, M.M.; Knopf, J.; Palomo, T.; Giordano, J.J.; Morse, S.A.; Fornari, F.; Barh, D.; Femino, J.; Bailey, J.A. Generational association studies of dopaminergic genes in REWARD DEFICIENCY SYNDROME (RDS) subjects: Selecting appropriate phenotypes for reward dependence behaviors. Int. J. Environ. Res. Public Health, 2011, 8(12), 4425-4459. doi: 10.3390/ijerph8124425 PMID: 22408582
  167. Blum, K.; Modestino, E.J.; Baron, D.; Brewer, R.; Thanos, P.; Elman, I.; Badgaiyan, R.D.; Downs, B.W.; Bagchi, D.; McLaughlin, T.; Bowirrat, A.; Roy, A.K.; Gold, M.S. Endorphinergic enhancement attenuation of POST-TRAUMATIC STRESS DISORDER (PTSD) via activation of neuro-immunological function in the face of a virus pandemic. Curr. Psychopharmacol., 2021, 10(2), 86-97. doi: 10.2174/2211556009999210104221215 PMID: 34466374
  168. Palmer, R.; Brick, L.; Nugent, L.; Bidwell, L.; McGeary, J. Examining the role of common genetics variants on alcohol, tobacco, cannabis, and illicit drug dependence. Addiction, 2015, 110, 530-537. doi: 10.1111/add.12815 PMID: 25424661
  169. Blum, K.; Chen, A.L.; Chen, T.J.H.; Braverman, E.R.; Reinking, J.; Blum, S.H.; Cassel, K.; Downs, B.W.; Waite, R.L.; Williams, L.; Prihoda, T.J.; Kerner, M.M.; Palomo, T.; Comings, D.E.; Tung, H.; Rhoades, P.; Oscar-Berman, M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of REWARD DEFICIENCY SYNDROME (RDS): A commentary. Theor. Biol. Med. Model., 2008, 5(1), 24. doi: 10.1186/1742-4682-5-24 PMID: 19014506
  170. Blum, K.; Chen, A.L.C.; Giordano, J.; Borsten, J.; Chen, T.J.H.; Hauser, M.; Simpatico, T.; Femino, J.; Braverman, E.R.; Barh, D. The addictive brain: All roads lead to dopamine. J. Psychoactive Drugs, 2012, 44(2), 134-143. doi: 10.1080/02791072.2012.685407 PMID: 22880541
  171. Blum, K.; Chen, T.J.H.; Morse, S.; Giordano, J.; Chen, A.L.C.; Thompson, J.; Allen, C.; Smolen, A.; Lubar, J.; Stice, E.; Downs, B.W.; Waite, R.L.; Madigan, M.A.; Kerner, M.; Fornari, F.; Braverman, E.R. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. Postgrad. Med., 2010, 122(6), 214-226. doi: 10.3810/pgm.2010.11.2237 PMID: 21084796
  172. Blum, K.; Braverman, E.; Carbajal, J. Hypothesizing synergy between acupuncture/auriotherapy and natural activation of mesolimbic dopaminergic pathways: Putative natural treatment modalities for the reduction of drug hunger and relapse. Integrative Omics and Applied Biotechnology Letters, 2011, 1, 1-14.
  173. Gilley, E. Integrating the Science of Addiction and the Science of Wellbeing. J. Alcohol. Drug Depend., 2017, 5(4), 2781. doi: 10.4172/2329-6488.1000275
  174. Blum, K.; Thanos, P.K.; Gold, M.S. Dopamine and glucose, obesity, and reward deficiency syndrome. Front. Psychol., 2014, 5, 919. doi: 10.3389/fpsyg.2014.00919 PMID: 25278909
  175. Archer, T.; Badgaiyan, R.D.; Blum, K. Physical exercise interventions for drug addictive disorders. J. Reward Defic. Syndr. Addict. Sci., 2017, 3(1), 17-20. doi: 10.17756/jrdsas.2017-036 PMID: 29034367
  176. Finan, P.H.; Letzen, J.; Epstein, D.H.; Mun, C.J.; Stull, S.; Kowalczyk, W.J.; Agage, D.; Phillips, K.A.; Pizzagalli, D.A.; Preston, K.L. Reward responsiveness in patients with opioid use disorder on opioid agonist treatment: Role of comorbid chronic pain. Pain Med., 2021, 22(9), 2019-2027. doi: 10.1093/pm/pnab031 PMID: 33624802
  177. Prendergast, M.L.; Podus, D.; Chang, E.; Urada, D. The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. Drug Alcohol Depend., 2002, 67(1), 53-72. doi: 10.1016/S0376-8716(02)00014-5 PMID: 12062779
  178. Moses, T.E.H.; Burmeister, M.; Greenwald, M.K. Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation. Addict. Biol., 2020, 25(3), e12777. doi: 10.1111/adb.12777 PMID: 31192519
  179. Leyton, M. Altered dopamine transmission as a familial risk trait for addictions. Curr. Opin. Behav. Sci., 2017, 13, 130-138. doi: 10.1016/j.cobeha.2016.11.011
  180. Luz, M.; Mash, D. Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse. Expert Opin. Drug Metab. Toxicol., 2021. doi: 10.1080/17425255.2021.1944099
  181. Volkow, N. Harnessing the power of science to inform substance abuse and addiction policy and practice; National Institute on Drug Abuse, 2014.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024